Trial Profile
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs Ensartinib (Primary)
- Indications CNS cancer; Ependymoma; Ewing's sarcoma; Glioma; Hepatoblastoma; Langerhans cell histiocytosis; Medulloblastoma; Neuroblastoma; Non-Hodgkin's lymphoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
- Focus Therapeutic Use
- Acronyms Pediatric MATCH
- 24 Dec 2022 Status changed from suspended to recruiting.
- 02 Nov 2022 Status changed from recruiting to suspended.
- 08 Apr 2022 Status changed from suspended to recruiting.